|
YAMAGUCHI SHIGEKI
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Position Professor and Division head |
|
| Article types | Original article |
| Language | English |
| Peer review | Non peer reviewed |
| Title | Enhanced Clinical Utility of Molecular Budding Signature as a Recurrence Risk Determinant in Stage II and III Colon Cancer Patients |
| Journal | Formal name：Annals of surgical oncology Abbreviation：Ann Surg Oncol ISSN code：15344681/10689265 |
| Domestic / Foregin | Foregin |
| Volume, Issue, Page | 30(8),pp.5239-5247 |
| Author and coauthor | SHINTO Eiji, OKI Eiji, SHIMOKAWA Mototsugu, YAMAGUCHI Shigeki, ISHIGURO Megumi, HASEGAWA Seiji, TAKII Yasumasa, ISHIDA Hideyuki, KUSUMOTO Tetsuya, MORITA Masaru, TOMITA Naohiro, SHIOZAWA Manabu, TANAKA Masafumi, OZAWA Heita, HASHIGUCHI Yojiro, OHNUMA Shinobu, TADA Sachiyo, MATSUSHIMA Tomoko, YAMAGISHI Keisuke, HASE Kazuo |
| Publication date | 2023/08 |
| Summary | BACKGROUND:A molecular budding signature (MBS), which consists of seven tumor budding-related genes, was recently presented as a prominent prognostic indicator in colon cancer (CC) using microarray data acquired from frozen specimens. This study aimed to confirm the predictive power of MBS for recurrence risk based on formalin-fixed, paraffin-embedded (FFPE) materials.METHODS:This research utilized the same microarray data from a prior multicenter study using FFPE whole tissue sections, which retrospectively reviewed 232 stage II CC patients without adjuvant chemotherapy and 302 stage III CC patients with adjuvant chemotherapy. All patients underwent upfront curative surgery without neoadjuvant therapy between 2009 and 2012. An MBS score was calculated using the mean of log2 [each signal] of seven genes (MSLN, SLC4A11, WNT11, SCEL, RUNX2, MGAT3, and FOXC1) as described before.RESULTS:The MBS-low group exhibited a better relapse-free survival (RFS) than the MBS-high group in stage II (P = 0.0077) and in stage III CC patients (P = 0.0003). Multivariate analyses revealed that the MBS score was an independent prognostic factor in both stage II (P = 0.0257) and stage III patients (P = 0.0022). Especially among T4, N2, or both (high-risk) stage III patients, the MBS-low group demonstrated markedly better RFS compared with the MBS-high group (P = 0.0013).CONCLUSIONS:This study confirmed the predictive power of the MBS for recurrence risk by employing FFPE materials in stage II/III CC patients. |
| DOI | 10.1245/s10434-023-13594-1 |
| PMID | 37154970 |